90 related articles for article (PubMed ID: 24403504)
1. From platinum compounds to targeted therapies in advanced thoracic malignancies.
Jakopovic M; Thomas A; Lopez-Chavez A
Anticancer Res; 2014 Jan; 34(1):477-82. PubMed ID: 24403504
[TBL] [Abstract][Full Text] [Related]
2. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
3. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib in the treatment of non-small-cell lung cancer.
Forde PM; Rudin CM
Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
7. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
D'Arcangelo M; Wynes MW; Hirsch FR
Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
[TBL] [Abstract][Full Text] [Related]
8. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
[TBL] [Abstract][Full Text] [Related]
9. Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer.
Pennell NA
Clin Lung Cancer; 2011 Nov; 12(6):350-9. PubMed ID: 21723791
[TBL] [Abstract][Full Text] [Related]
10. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
Langer CJ; Mok T; Postmus PE
Cancer Treat Rev; 2013 May; 39(3):252-60. PubMed ID: 22703830
[TBL] [Abstract][Full Text] [Related]
11. Dacomitinib, a new therapy for the treatment of non-small cell lung cancer.
Brzezniak C; Carter CA; Giaccone G
Expert Opin Pharmacother; 2013 Feb; 14(2):247-53. PubMed ID: 23294134
[TBL] [Abstract][Full Text] [Related]
12. [Driver gene mutation and targeted therapy of lung cancer].
Mitsudomi T
Gan To Kagaku Ryoho; 2013 Mar; 40(3):285-90. PubMed ID: 23507588
[TBL] [Abstract][Full Text] [Related]
13. Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer.
Nakata A; Gotoh N
Expert Opin Ther Targets; 2012 Aug; 16(8):771-81. PubMed ID: 22762482
[TBL] [Abstract][Full Text] [Related]
14. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
16. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
18. The current status of targeted therapy for non-small cell lung cancer.
Francis H; Solomon B
Intern Med J; 2010 Sep; 40(9):611-8. PubMed ID: 20002849
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic lymphoma kinase as a therapeutic target.
Kruczynski A; Delsol G; Laurent C; Brousset P; Lamant L
Expert Opin Ther Targets; 2012 Nov; 16(11):1127-38. PubMed ID: 22998583
[TBL] [Abstract][Full Text] [Related]
20. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
Langer C; Soria JC
Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
